Saturday, December 3, 2022

561.316.3330

Biotechnology News Magazine

NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

NeuroSigma, Inc., a bioelectronic medical device company, today announced that a team at the University of California, Los Angeles (UCLA) led by Professor Sandra Loo received a National Institutes of Health (NIH) grant to conduct a double-blind randomized controlled trial of eTNS for pediatric attention-deficit/hyperactivity disorder (ADHD). The trial will enroll up to 225 children with moderate to severe ADHD at UCLA and Seattle Children’s Hospital for a blinded period of 4 weeks followed by an open label follow-up period of up to 1 year. Professor James McGough will be the Co-Lead at UCLA and Professor Mark Stein will lead the team at Seattle Children’s Hospital.

“We would like to thank Professor Loo and her team at UCLA as well as Professor Stein and his colleagues at Seattle Children’s for their successful efforts to obtain NIH funding for this important project,” said Dr. Colin Kealey, President of NeuroSigma. “With this study and the recently-announced clinical trial of eTNS for pediatric ADHD at King’s College London, NeuroSigma continues to execute on its strategy of working with leading academic centers to build out a world-class dataset supporting the clinical use of eTNS for pediatric ADHD.”

Building on earlier work at UCLA, this trial is designed to demonstrate the safety and efficacy of eTNS in a larger trial and validate certain hypotheses about the therapy’s mechanism of action, including the possibility of predicting responders with cognitive and EEG tests prior to initiating therapy. Funding for the 4-week blinded period is provided by NIH Grant 1R01MH126041-01A1 with devices and funding for the long-term open label period provided by NeuroSigma.

“We look forward to starting enrollment for this trial in the next few months,” commented Professor Loo. “There is a clear need for non-pharmacologic treatment options in pediatric ADHD. If successful, this trial will confirm the safety and efficacy of eTNS in this patient population, provide further validation of neural mechanisms of action, and provide clinicians with screening tools to predict which patients are good candidates for the therapy.”

More information about the study can be found at the following website: https://www.semel.ucla.edu/adhdandmood

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine